Omnicare Inc

Omnicare — Q4 2012 Earnings Presentation

17 slides from Omnicare's earnings presentation, Feb 19, 2013

  1. Slide 1: Omnicare

    Omnicare

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain of mace lovey it i the following re fe ‘d-lookit i i vate ities Litigation Reform Act of 1995. These forward-| looking statements include, but are not tte to, all statements ir ue intent, belief or Current regarding Such and involve k and orleaan risks, uncertainti

  3. Slide 3: Table of Contents

    Table of Contents Fourth-Quarter 2012 HIGhlQhts a .crssssssecasereesascasca ces cocwacwavesaeaeioeeeaternesert A Operating Metrics — Script Data | Operating Metrics — Long-Term Care Bed Data... Gross Profit & Adjusted Operating Income Adjusted Net Income & Cash-based EPS.... Adjusted Operating Incom

  4. Slide 4: Fourth-Quarter 2012 Highlights

    Fourth-Quarter 2012 Highlights Gross profit 4.7% higher than 4Q11 to $376.7M; 152 bps margin increase Adjusted Cash-Based EPS) of $0.86; 10.3% higher than 4Q11 of $0.78 Cash flows from operations of $127.6M; 25.7% increase over last year $292.4 million returned to shareholders through share repurcha

  5. Slide 5: Operating Metrics - Script Data

    Operating Metrics Script Data Sequential Increase (In thousands, except %s) 4Q2012 32012 (Decrease) Long-Term Care Group Scripts: Generic scripts dispensed 21,109 20,586 2.5% Branded scripts dispens 4049 4,083 (0.8%) Over-the-counter scripts dispensed 3,561 3,492 fo Total LTC Group scripts 28,719 _

  6. Slide 6: Operating Metrics - Long-Term Care Bed Data

    Operating Metrics Long-Term Care Bed Data Sequential Prior Year Increase / Increase / (In thousands) 4Q2012 32012 (Decrease) _4Q2011__(Decrease) served: Beginning of period - LTC Beds 980 97 3 1,008 (28) Net change in beds served (10) 3 (13) 2 (12) End of period - LTC Beds 970 980 (10) 1,010 (40) Pa

  7. Slide 7: Gross Profit & Adjusted Operating Income

    Gross Profit & Adjusted Operating Income (8) In millions, except per share data and %s Net sales Cost of sales Gross profit Rate SG&A expenses Provision for doubtful accounts Adjusted operating income ©) Rate Sequential 4Q2012_ _ 3.2012 $ 1,529.9 $ 1,501.3 1,153.3 4,130.1 $ 3767 $ 371.3 24.62% 24.73

  8. Slide 8: Adjusted Net Income & Cash-based EPS

    Adjusted Net Income & Cash-based EPS) i Sequential Prior Year Increase / In milions, except per share data and %s 4Q 2012 30.2012 (oases) 4Q.2011_ _(Decrease| Adjusted operating income $1357 $ 1437 (6.6%) § 134.4 1.0% Adjusted interest expense, net of imesiment income (237) (24.9) (4.8%) (25.8) (7.4

  9. Slide 9: Adjusted Operating Income by Segment

    iH 2 Adjusted Operating Income by Segment “) Sequential Prior Year Increase / Increase / 402012 _3Q2012_ _(Decrease| 4Q 2011 He pinto: except %S Care Group sales $ 1,183.6 $ 1,165.7 1.5% $ 1,277.4 (7.3%) ‘Adjusted operating income from continuing operations 155.0 154.4 0.4% 146.3 5.9% Rate 73.10% 13

  10. Slide 10: Cash Flows

    Cash Flows") Sequential Prior Year Increase Increase / iG dae except %s 4.2012 30.2012 (Decrease) 40.2011 (Decrease! in 5 61 (3.9%) $312 89.1% | 2 fom discontinued operat - - : 74 (100.0%) pdjstments to reconcile vet income to net cash flows from operating Depreciation expense 137 13.8 (0.7%) 11.5 1

  11. Slide 11: Cash Deployment

    Cash Deployment In millions, except %s Increase / Increase / 4Q2012 30.2012 (Decrease) _4@2011_ (Decrease) Net cash flows from operating activities of continuing operations (reported) $1276 $ 1963 (35.0%) $ 101.5 25.7% Capital xpenditures 28.5 25.0 14.0% 23.7 20.3% Acquisit 05 33.8 (98.5%) of 400.0%

  12. Slide 12: Full-Year 2013 Guidance

    Full-Year 2013 Guidance Pe FY2013 r | 20r2 ests | Guidance “) % Change + Revenue $6.2B $6.1B to $6.2B -1.6% to 0.0% Adjusted cash earnings 5 5 per diluted share) $3.36 $3.47 to $3.57 3.3% to 6.3% Cash flow from operations® $544M $450M to $500M -17.3% to -8.1% 4k povnon Fay 9.8 ios 2 Ete soeme poms 8

  13. Slide 13: Appendix

    Appendix

  14. Slide 14: Capital Structure

    Capital Structure Major Debt Maturity Schedule” (ins $ million $1,800 $1,500 wAs of 9/30/10 wAs of 12/31/12 $1,200 $900 $600 $300 | 2010 2015 2020 2025 2030 2035 2040

  15. Slide 15: Working Capital Management

    Working Capital Management Five Quarter Trend) 40 70 308 30 é —————— — S ie 273 20 © 56.7 55.0 ‘5a2: 10 ~~ 0 SLE 50 4Qil 1Q12 2Q12 3Q12 4Q12 1. _DOH= Ending Inventory (Quarry Cost of Sales /Daysin Quart) DSO = Ending Account Receivable (Quartet Sles/Daysin Quai) 2 omnicare

  16. Slide 16: Selected Branded Drug Patent Expirations

    Selected Branded Drug Patent Expirations),2) 4Q 2012 FY 2013 Atacand HCT Aciphex Comtan Asacol Dilantin Intatabs Atacand IR Diovan HCTZ Cymbalta Gabitril Diovan IR Maxalt Lidoderm Revatio Lunesta Sanctura XR Mucinex (relaunch) Tricor Niaspan Oxycontin Prevacid Soltab (relaunch) rugs read unched show

  17. Slide 17: Omnicare

    Omnicare

Omnicare — Q4 2012 Earnings Presentation on 6ix